36.1 C
Vientiane
Friday, April 25, 2025
spot_img
Home Blog Page 771

Luzerne’s Craftsmanship Helps Dehua Ceramic Trade Association (China) Secure Guinness World Records Title for Largest Porcelain Car Sculpture (supported)

SINGAPORE, Jan. 13, 2025 /PRNewswire/ — Luzerne Pte Ltd is proud to announce its crucial role in helping the Dehua Ceramic Trade Association (China) secure the GUINNESS WORLD RECORDS™ title for producing the largest porcelain sculpture of a car (supported). Guinness World Records is the global authority on record-breaking achievements, with strict criteria for titles, including measurability, standardisation, verifiability, and the requirement to be the best in the world.

Selina Tang, CEO, with Luzerne staff celebrating the Guinness World Records™ title for the Largest Porcelain Car Sculpture (Supported), achieved in collaboration with the Dehua Ceramic Trade Association (China).
Selina Tang, CEO, with Luzerne staff celebrating the Guinness World Records™ title for the Largest Porcelain Car Sculpture (Supported), achieved in collaboration with the Dehua Ceramic Trade Association (China).

On 14 August 2024, Luzerne’s craftsmanship officially broke the record for producing the world’s first car model fully sculpted in porcelain on a scale of 1:1 and weighing in at an impressive 1.4 tonnes. According to officials from Guinness World Records, onsite measurements of the car show a body length of 5.51 metres, a width of 2.15 metres and a height of 1.39 metres, giving a combined measurement of 9.05 metres. This exceeds the minimum requirement of 8 metres for an entry in this category, thereby being listed officially in the Guinness World Records Hall of Fame.

In collaboration with the Dehua Ceramic Trade Association in China, Luzerne Pte Ltd spent 11 months accomplishing this feat in its wholly-owned factory situated in the county. Dehua, Fujian province, China, is the birthplace of Blanc de Chine, a name given to porcelain celebrated for its soft ivory-white hue, which is also manifested on the car’s exterior. In 2021, the kilns of Dehua were inscribed on the UNESCO World Heritage List. The Chinese government had also conferred it the honour of the National Civilised City Award (NCCA) to boost its development and status as the World’s Porcelain City.

The feat is also a significant testament to the craftsmanship of the 50 craftsmen who worked on the project. The sheer size of the sculpture and its complicated form have thus added to the difficulty of this challenge. “The team of 50 boasts diverse skillsets, so we benefited greatly from teamwork to accomplish this feat; it is impossible to do it alone. Dehua is the world’s porcelain city and we have a mission to spread its name afar,” explained Mr Peter Lek, Managing Director of Hiap Huat Holdings Pte Ltd and Chairman of Luzerne Pte Ltd.

The Dehua county government also elaborated that it will continue exploring new inroads in ceramic culture and art, breaking frontiers in its global recognition and raising market competitiveness. This is in its overall vision of using Blanc de Chine as a conversation intermediary with the rest of the world.

About Luzerne

Luzerne has been designing and producing bespoke quality tableware for some of the world’s most renowned restaurants, hotels and chefs since 2004. We pioneered the creation of fine china without animal bone ash, and the Luzerne factory in Dehua is the first in the world to be Halal-certified. We are also humbled to be named the Century Best Brand in China in 2019.

Drawing on over 75 years of expertise, we became Singapore’s first tableware manufacturer to develop its own line of products and produces up to 28 million pieces of ceramic and stone tableware annually at our fully-automated factory in Dehua. Our strategic location in Dehua, China comes as no surprise for the charming county is historically the birthplace of Blanc de Chine Dehua also holds several accolades such as The World Porcelain City and The National Civilised City Award conferred by the Chinese government. In 2021, its kilns were ceremoniously inscribed on the UNESCO World Heritage List.

Luzerne’s global presence in over 60 countries is supported by 800 employees in 5 offices in China (Shanghai, Xiamen, Dehua), Cambodia, and our headquarters in Singapore. Luzerne tableware is used in restaurants and hotels globally, and can also be experienced in the skies with Singapore Airlines. It is the preferred brand with renowned hospitality chains.

For more information, please visit www.luzerne.com.

About Guinness World Records

Guinness World Records™ is the global authority on record-breaking achievements. Established in 1955, the organisation has become synonymous with documenting extraordinary feats, unique talents, and remarkable accomplishments across the world. With a mission to celebrate the best in human endeavour and to inspire people of all ages, cultures, and nationalities, Guinness World Records™ continues to push the boundaries of what is possible.

Each year, millions of people attempt to break records, and only the most extraordinary are awarded the official Guinness World Records™ title. From awe-inspiring human achievements to groundbreaking technological advancements, Guinness World Records™ recognises and honours the incredible potential of individuals, teams, and organisations worldwide.

For more information, please visit www.guinnessworldrecords.com.

Gianna Lullume Baby Soother Device Officially Launches on Kickstarter

HONG KONG, Jan. 13, 2025 /PRNewswire/ — Gianna Lullume, an innovative brand committed to improving infant sleep and promoting family well-being, is proud to announce the official launch of its crowdfunding campaign on Kickstarter. Designed for infants and toddlers aged 0-4, the Gianna Lullume Baby Soother Device offers a cutting-edge solution to one of parenting’s most significant challenges: sleepless nights.

Gianna Lullume Baby Soother Device
Gianna Lullume Baby Soother Device

https://www.kickstarter.com/projects/giannalullumesoother/gianna-baby-soother-with-cry-detection

This advanced sleep device integrates cry detection technology, sound therapy, and red-light therapy to create a soothing, smart sleep environment. The result? Better sleep for babies and peace of mind for parents.

Key Features:

  • Cry Detection Technology: Detects a baby’s cry within 20 seconds and automatically responds with calming sounds and lights to soothe the baby before their distress escalates.
  • Red Light Therapy: Scientifically designed red light promotes melatonin production, supporting natural sleep cycles without disrupting the baby’s rest.
  • Sound Therapy: Offers a variety of soothing options, including white noise, pink noise, nature sounds, and womb-like heartbeats, all optimized for infant relaxation and safety.
  • Smart App Control: Enables parents to remotely manage settings, timers, and notifications, ensuring convenience and customization.

“At Gianna Lullume, we believe that a better sleep for babies translates to a better sleep for the entire family,” said Simon Shawn, CEO of Gianna. “Our mission is to equip parents with intelligent tools that bring comfort to their little ones while fostering a calm and restful home environment.”

Join the Movement

The Kickstarter campaign is now live, offering exclusive early-bird rewards for backers who choose to join the mission to redefine sleep for families worldwide. Supporters can visit the campaign page at Kickstarter to learn more about the product and secure special launch perks.

About Gianna Lullume

Founded with the vision of improving the lives of families through science-backed sleep solutions, Gianna Lullume specializes in innovative devices designed to support infants and toddlers. By combining thoughtful design, advanced technology, and a deep understanding of parental needs, Gianna Lullume aims to make restful nights a reality for families everywhere.

Sleepless or Restless?Soothing Your Little One with Gianna Lullume.

For media inquiries, please contact:
market@giannashop.com

Gianna Branding Team
brand@kerchangroup.com 

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ — Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S.

Cooperation of Simcere Zaiming and Abbvie
Cooperation of Simcere Zaiming and Abbvie

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.

“As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations,” said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. “We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma”

“SIM0500 is developed via Simcere Zaiming’s proprietary T-cell engager platform,” said Renhong Tang, PhD, CEO of Simcere Zaiming. “We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. ”

Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory

About AbbVie in Oncology

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie’s Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

About Simcere Zaiming

Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, “Simcere”). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.

LG Innotek Reasserts Its Leadership in the Future Mobility Market at CES 2025

  • Exhibition booth attracts 65,000 cumulative visitors, showcasing innovative mobility components
  • Innovative technologies presented through a ‘User-Centric storytelling’ approach elicit strong acclaim, inquiries from visiting customers ensue

SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ — On the 13th, LG Innotek (CEO Moon Hyuksoo) announced that it successfully staged its exhibition at CES 2025 held in Las Vegas, USA.

Visitors at LG Innotek's CES 2025 Exhibition Booth
Visitors at LG Innotek’s CES 2025 Exhibition Booth

Situated at the entrance of the West Hall of the Las Vegas Convention Center (LVCC), LG Innotek’s exhibition booth attracted a steady stream of visitors from its opening on the first day of the CES event, on January 7th (local time).

Visitors at LG Innotek's CES 2025 Exhibition Booth
Visitors at LG Innotek’s CES 2025 Exhibition Booth

During the four-day exhibition period that lasted until the 10th, more than 65,000 visitors were recorded at the LG Innotek booth. Many visitors showed great interest, leading to product inquiries and on-the-spot meeting requests.

A company representative said, “This year, we prominently displayed a 1,800-inch large-scale video advertisement in the Main Hall of the West Hall and a 9-meter-tall banner at the booth entrance, effectively enhancing brand awareness and exhibition promotion.”

At CES 2025, LG Innotek focused its exhibition on the theme of mobility to solidify its position as a ‘Total Solution Provider’ in the global market for future mobility.

In particular, LG Innotek designed its open booth with a sleek, futuristic black aesthetic, showcasing not only a future vehicle mockup but also its new brand identity, ‘ENABLE THE NEXT’, and the slogan, ‘YOUR ASPIRATION, OUR INNOVATION.’

At the center of the exhibition booth, the future vehicle mockup displayed 15 key components for sensing, communication, and lighting. Additionally, the high-value vehicle lighting module, Nexlide A+, which won the CES 2025 Innovation Award, garnered significant attention.

LG Innotek Nexlide showcased at CES 2025
LG Innotek Nexlide showcased at CES 2025

In the expanded private booth, which was 30% larger than the previous year, various innovative and integrated solutions combining optical, communication, and automotive technologies were presented through an immersive User-Centric storytelling approach, receiving positive feedback.

Among these, the RGB-IR In-Cabin Camera Module, unveiled for the first time at CES 2025, stood out. This camera can monitor driver conditions, such as detecting drowsiness, and alert the driver immediately.

An LG Innotek employee demonstrating the In-Cabin Camera Module at CES 2025
An LG Innotek employee demonstrating the In-Cabin Camera Module at CES 2025

Unlike conventional models, this new module features a 150-degree field of view, enabling simultaneous monitoring of the driver, front passenger, and rear passengers. It integrates a 5-megapixel RGB camera, an IR camera for low-light environments, and a 3D camera that supports facial recognition for functions like login and payment.

When a driver logs in using facial recognition, settings such as radio channels and air conditioning levels, adjusted by previous drivers, are automatically switched to the new driver’s preferences. A North American customer said, “It’s impressive how such advanced features, which enhance convenience for drivers, are incorporated into a single small camera module.”

The innovation of ‘Nexlide Vision,’ developed with LG Innotek’s proprietary vehicle lighting technology, also drew attention. Combining pixel lighting and smart film technology, this product can implement pixels, surfaces, and lines simultaneously.

For instance, by writing a desired message on the adjacent pad, the text instantly appears on the vehicle’s lighting grill. This innovative application demonstrated how advanced communication capabilities can be integrated into vehicle lighting.

A customer who experienced Nexlide Vision’s lettering feature said, “If an emergency stop is required while driving, it’s possible to use Nexlide Vision to communicate specific reasons to following vehicles, potentially preventing accidents. LG Innotek’s technology is truly remarkable.”

Furthermore, LG Innotek’s comprehensive lineup of mobility solutions, including the Next-Generation Digital Key Solution, Vehicle AP Module, All-Weather Camera Solution, and the groundbreaking B-Link, which combines a wireless Battery Management System (BMS) with a Battery Junction Box (BJB), were prominently showcased at CES 2025.

CEO Moon Hyuksoo stated, “Through CES 2025, LG Innotek has further strengthened its position as a leader in future mobility components. We will continue to deliver innovative solutions that provide differentiated value to customers and grow as the reliable technology partner enabling our customer’s aspiration.”

LG Innotek CEO Moon Hyuksoo
LG Innotek CEO Moon Hyuksoo

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

– Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine
– Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications

SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ — Since the COVID-19 pandemic, mRNA vaccines have been recognized as the most important platform for infectious disease prevention and continue to be utilized across various fields. However, concerns remain about the limitations of the technology, including the need for ultra-cold storage and side effects associated with lipid nanoparticles (LNP) required for mRNA delivery.

Recently, new platforms are emerging as alternatives to mRNA vaccines.

One such platform is the Virus-Like Particle (VLP) vaccine technology. While not as widely known as mRNA vaccines, Ferritin based nano platform VLP vaccines have been noted for their potential to significantly enhance immune responses due to their structural stability. VLPs mimic the structural characteristics of target viruses, presenting antigens in a virus-like configuration. Particularly, the Ferritin based nano platform VLP vaccine is being evaluated as a powerful platform capable of accommodating multiple virus antigens simultaneously, making it suitable for addressing various mutations.

DXVX(180400) has recently acquired global development rights from Stanford University for an innovative universal coronavirus vaccine based on the Ferritin based nano platform VLP technology. Through the dedication and persuasive efforts of Chong-Yoon Lim, Chairman of the COREE Group and major shareholder of DXVX, this collaboration was established.

Ferritin, a protein that stores iron, can self-assemble into hollow spherical nanoparticles depending on pH conditions. Dx&Vx’s VLP vaccine utilizes this ferritin-based nanoparticle platform to display the spike protein of the coronavirus on its surface, making a universal coronavirus vaccine. The Ferritin-based VLP vaccine structurally mimics the size and shape of the COVID-19 virus, enabling the immune system to recognize it as the actual virus. This VLP vaccine can induce a strong cytotoxic T-cell response, effectively combating viral infections.

The human immune system defends against viral infections through both humoral and cellular immune responses, a process known as ‘cross-presentation.’ Vaccines that stimulate both immune systems simultaneously provide more robust and long-lasting immunity compared to vaccines that only induce antibody production.

Cytotoxic T cells, which play a critical role in destroying virus-infected or cancerous cells, do not directly recognize antigens. Instead, T cells only identify antigen fragments presented by major histocompatibility complex (MHC) molecules, thereby targeting and eliminating infected cells.

Notably, Dx&Vx’s vaccine is designed to strongly induce both humoral and cellular immune responses, making it superior to traditional antigen protein-based vaccines that primarily focus on humoral immunity. The Ferritin-based VLP vaccine, now preparing for global Phase 2 clinical trials, is expected to demonstrate superior immune induction effects compared to marketed vaccines.

VLP vaccine image
VLP vaccine image

According to animal studies conducted by the Walter Reed Army Institute of Research (WRAIR), the Ferritin-based VLP vaccine demonstrated neutralizing antibody levels more than ten times higher than those of mRNA vaccines. Additionally, the Wuhan Institute of Virology in China reported that the Ferritin-based VLP vaccine outperformed mRNA vaccines. Collectively, these findings indicate that the Ferritin-based VLP vaccine may offer superior protective effects compared to traditional vaccine platforms.

Moreover, this vaccine has demonstrated stability at room temperature for up to two weeks and has shown the ability to induce strong immune responses even in previously unexposed organisms. These characteristics distinguish it from mRNA-based vaccines. The platform has also been validated for its applicability in polyvalent vaccines for broad mutation coverage, offering versatility in administration routes and various other advantages.

Ferritin-based vaccine can simultaneously activate both humoral and cellular immunity, whereas traditional vaccines primarily depend on humoral immunity (Global Journal ‘Vaccines’, December 2024)
Ferritin-based vaccine can simultaneously activate both humoral and cellular immunity, whereas traditional vaccines primarily depend on humoral immunity (Global Journal ‘Vaccines’, December 2024)

Dx&Vx’s VLP universal coronavirus vaccine has already completed Phase 1 clinical trials in the United States and South Africa, where it was evaluated against mRNA vaccines for antibody titers and adverse effects. The results have confirmed the technological superiority of this vaccine platform.

The Ferritin platform-based VLP vaccine is expected to be extended for the development of vaccines against various lethal viruses, such as influenza and Ebola, playing a critical role in future pandemic responses.

A Dx&Vx representative stated, “The ultimate goal of the Ferritin platform-based VLP vaccine under development is to provide a safe, superior, and convenient vaccine that offers maximum protection against various deadly infectious diseases for humanity.”

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS’ LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism.

DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /PRNewswire/ — ZEISS Medical Technology announced today that the MEL® 90 received approval from the U.S. Food and Drug Administration (FDA), giving the excimer laser technology simultaneous approval for all three major indications, including myopia, hyperopia and mixed astigmatism (a condition where both hyperopic and myopic correction is required). The ZEISS MEL 90 fully integrates into the Corneal Refractive Workflow to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro from ZEISS to help further broaden a surgeon’s refractive business with improved patient attraction and positive clinical outcomes.

ZEISS MEL 90 Excimer Laser
ZEISS MEL 90 Excimer Laser

“The increasing global adoption of laser vision correction reflects the advancements and positive impact the technology continues to have on the quality of life for patients,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with greater workflow efficiency and performance with enhanced outcomes.”

“ZEISS continues to break new ground as a leader in the LVC market, reflecting our ongoing commitment to and support of U.S. surgeons and patients with the latest refractive innovation that helps set practices apart and provides more options to more patients,” says Andrew Chang, Head of Global Sales for ZEISS Medical Technology. “With the availability of the ZEISS MEL 90 in the U.S. market, surgeons can now offer an integrated workflow of refractive technology to help reach new patients and provide excellent outcomes for them.”

“The FDA approval of the ZEISS MEL 90 excimer laser is a game changer for refractive surgery in the U.S. This advanced technology, with its Triple-A ablation algorithm and fast ablation speed, sets a new benchmark for precision, safety, and efficiency. I am particularly impressed by the system’s ability to simplify treatment planning while delivering highly predictable and tissue-conserving results. The integration of the ZEISS MEL 90 with the ZEISS VISUMAX 800 femtosecond laser opens new doors for streamlined workflows and optimal patient outcomes. This approval marks an exciting chapter for surgeons and patients alike,” says Dr. John Doane, Refractive Surgeon, Discover Vision Centers, Kansas City, MO.

Reliable Outcomes: The ZEISS MEL 90 offers Triple-A (Advanced Ablation Algorithm), which is a single ablation profile for a wide range of sphero-cylindrical (SCA) corrections that simplifies treatment planning. Triple-A offers a high degree of accuracy, reproducibility and predictability, as well as advantages such as tissue-saving ablation. Its preinstalled functions also offer surgeons optimal support for achieving excellent treatment results and gentle treatments of standard, higher and lower levels of ametropia and astigmatism.

Fast Ablation Speed: The ZEISS MEL 90 offers a truly customized power package. When performing LASIK for myopia at 500 Hz, the ZEISS MEL 90 can intra-operatively ablate 1 diopter in as little as 1.3 seconds.1 Intuitive system guidance and speedy treatment planning allow for additional time savings. The ZEISS MEL 90 excimer laser technology is equipped with an active eye tracker which delivers an excellent response time, providing a high level of treatment safety with very stable results.

Easy to Use: New capabilities of the ZEISS MEL 90 excimer laser greatly simplify the interactions between the surgeon, the assisting staff and the system technology. The excimer laser can be configured to precisely match the surgeon and the OR team’s needs. The system’s simple, intuitive graphic user interface supports fast treatment procedures, and the touch screen can be flexibly positioned wherever it is needed to enable the surgeon to have good ergonomic sitting posture throughout an operation. A second, optional touch screen can be configured to optimally complement the treatment routine of the OR team. An HD video port, network printer connection, and PDF export capabilities offer additional workflow support.

With the ZEISS MEL 90, the company expands its offerings for U.S. refractive clinics and helps support the improvement of clinical outcomes and patient satisfaction through onboarding, training, service support and ZEISS Practice Development Consulting.

The ZEISS MEL 90 excimer laser is currently available in the U.S. For more information, visit www.zeiss.com/us/mel-90

1LASIK myopia, optical zone 6 mm.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Trillium Flow Technologies Successfully Completes Refinancing

STAMFORD, Conn., Jan. 13, 2025 /PRNewswire/ — Trillium Flow Technologies (“Trillium”), a portfolio company of First Reserve, and a global designer, manufacturer, and aftermarket services provider of highly engineered valves and pumps used in critical infrastructure sectors such as nuclear power, water, wastewater, and industrial processing, is pleased to announce the successful completion of its refinancing in December 2024.

The refinancing provides Trillium with extended maturity, enhanced liquidity, improved terms, and increased flexibility to support further M&A activity.

Kerem Yilmaz, Chief Financial Officer of Trillium, commented: “We are pleased to cap a successful 2024 with this significant milestone and to enter 2025 with strong momentum. We are excited about our new credit facility, which is led by funds managed by Blue Owl Capital Inc. (“Blue Owl”). We would also like to thank JP Morgan and BDTMSD for their continued commitment and support of our business. This refinancing positions us well to execute our organic growth strategy, which includes investing in innovation and operational excellence to better serve our customers. We aim to remain active in M&A as a leading player in the flow control industry.”

Matt Tier, Managing Director at Blue Owl, said: “Trillium has a long and successful track record as a global supplier and aftermarket service provider of mission-critical valves and pumps used in a variety of industries. We are excited to welcome Trillium as borrower in our direct lending portfolio and look forward to supporting Doug, Kerem and the rest of the leadership team as they execute on their growth strategy for the business in the years to come.”

Doug Kitani, Chief Executive Officer of Trillium, said: “I’d like to extend my deepest gratitude to our finance team, equity partner First Reserve, and our lead lender, Blue Owl, for their support throughout this successful refinancing, and I especially want to recognize our employees for their exceptional performance in 2024. This milestone reflects our collective dedication and positions Trillium for continued innovation, growth, and leadership in the global flow control industry.”

About Trillium Flow Technologies
Trillium Flow Technologies is a global designer, manufacturer, and aftermarket services provider specializing in highly engineered valves, pumps, and related products. Serving customers in critical infrastructure industries, Trillium is committed to delivering innovative solutions that enhance reliability, safety, and efficiency.

For more information, visit: www.trilliumflow.com.

About Blue Owl
Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives.

With $235 billion in assets under management as of September 30, 2024, we invest across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Estate. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation.

Together with over 1,050 experienced professionals, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com.

About First Reserve:
First Reserve is a leading global private equity firm investing across diversified energy, utility, and industrial end-markets. Founded in 1983, First Reserve has more than 40 years of industry insight and has cultivated a differentiated network of global relationships. The firm has raised over $34 billion of aggregate capital and has developed operational expertise built from over 750 transactions, including platform investments and add-on acquisitions. For more information, visit www.firstreserve.com.

Media Contact
Chris Molineaux
Global Marketing and Communications Director, Trillium Flow Technologies
media@trilliumflow.com

Neuromodulation Wristband ObeEnd Reduces Heart Rate and Perceived Exercise Exertion

VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ — WAT Medical Enterprise collaborated with Concordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designed by WAT for weight and health management. The study revealed that electroacupuncture may help improve exercise performance and post-exercise recovery by reducing heart rate and perceived exertion during physical activity.

Published in the International Journal of Environmental Research and Public Health, the study highlights the potential benefits of this neuromodulation technology based on traditional Chinese medicine technique for enhancing participation in physical activity.

The research involved 32 healthy participants, who underwent electroacupuncture sessions targeting the PC6 acupuncture point over the course of one week. The study employed the YMCA submaximal bike test to measure cardiovascular responses, including heart rate, systolic blood pressure, and perceived exertion levels.

Key findings included a significant reduction in heart rate during the most challenging stage of the exercise test, as well as a decreased perception of effort across all stages. Additionally, participants experienced quicker post-exercise recovery, with systolic blood pressure notably lower five minutes after completing the test. The proposed mechanism of action is through the modulation of the rostral ventrolateral medulla (RVLM), a key area in the brainstem that regulates cardiovascular function and arterial blood pressure.

The study suggests that electroacupuncture could be particularly useful for populations struggling with sedentary lifestyles or exercise-induced fatigue. By making exercise feel easier, this technique could encourage greater adherence to fitness routines, promoting better long-term health outcomes.

Possible application in hypertension management could also be explored in future studies, as the proposed mechanism has the potential to down-regulate the sympathetic nervous system and reduce blood pressure.

References:

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11507089/
  2. www.watmedical.com
  3. www.emeterm.com